US trade probe into German drug pricing draws EU industry pushback
American trade officials heard testimony on Tuesday regarding an investigation tied to Germany's declining payments for pharmaceuticals, with arguments both for and against the probe. EU-based pharma executives are urging greater competitiveness against the US and China, potentially influencing the outcome of the investigation.
The US trade investigation focuses on Germany's pharmaceutical reimbursement policies, where government payments for drugs have been trending downward. Tuesday's testimony featured stakeholders on both sides — some defending the pricing structure as a legitimate cost-control measure, others arguing it disadvantages American manufacturers seeking fair market access.
European pharmaceutical executives used the hearing to emphasize the need for stronger transatlantic competitiveness, pointing to pressure from both US and Chinese industry players. Their remarks suggest the probe's resolution may be shaped by broader geopolitical trade dynamics, not solely by the pricing dispute itself.
This probe could influence how governments and drugmakers negotiate pharmaceutical pricing across international markets. If the US acts on its findings, European manufacturers may face new trade barriers, while American consumers might see limited direct impact on domestic drug costs. European healthcare systems could be forced to reassess purchasing strategies, and the outcome may set a precedent for how other nations handle cross-border drug pricing disputes.